- Report
- January 2025
- 182 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- December 2024
- 186 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- July 2024
- 185 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- May 2025
- 110 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- October 2024
- 200 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- August 2024
- 60 Pages
Global
From €1347EUR$1,500USD£1,147GBP
- Report
- July 2024
- 150 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- July 2024
- 100 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- October 2024
- 264 Pages
Global
From €3995EUR$4,450USD£3,402GBP
- Report
- August 2024
- 200 Pages
Global
From €3995EUR$4,450USD£3,402GBP
- Report
- May 2025
- 110 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- August 2024
- 184 Pages
Global
From €2245EUR$2,500USD£1,912GBP
- Report
- April 2025
- 80 Pages
Global
From €1796EUR$2,000USD£1,529GBP
- Report
- July 2024
- 150 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- May 2025
- 190 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- April 2025
- 189 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- February 2025
- 187 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- January 2025
- 182 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- January 2025
- 182 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- November 2024
- 180 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more